In a speech delivered to Investors recently in Singapore, James Elliot; a senior partner in Hong Kong-based Venture Capital Firm Bradley Hill Holdings Ltd announced plans to expand their successful Biotech/Life Sciences division.
Elliot, who has been with Bradley Hill for over 10 years now, said that they would be utilizing “a global network of established partners and affiliates to keep our finger on the pulse of Research and Development in the Biotechnology field.”
Bradley Hill Holdings are believed to be involved with a select number of hand-picked startup enterprises who have what the firm’s associates say are “FDA-Approval failsafes”. The common focus of these enterprises is said to be nanotechnology – with a particular eye on products being offered to the ever-growing medical services sector. Indeed, with the baby-boomer trend causing an ever-increasing average age in humans, this strategy is seen by many to be another example of Bradley Hill showing a level of forward thinking that sets top-tier VC firms apart from the crowd.
Little is known of Bradley Hill Holdings current projects, due to stringent non-disclosure agreements which are put in place to protect the integrity of their clients, as yet unpatented products and technologies, but they are well known for their private funding of many successful startups, as well as proving business development and go-to-market planning skills to firms who are often comprised of primarily academic & scientific minds.
Bradley Hill Holdings were formed in 1981 and have been growing constantly since their formation, due in no large part to a handful of successful partnerships with dot-com wonderkids of the early-nineties and more recently, far-eastern biotech gurus, who have then gone on to sell out to industry kingpins such as GSK and Pfizer for astronomical gains.
This post was submitted by Max Siberski.
